Copyright
©The Author(s) 2024.
World J Gastrointest Pharmacol Ther. Nov 5, 2024; 15(6): 97381
Published online Nov 5, 2024. doi: 10.4292/wjgpt.v15.i6.97381
Published online Nov 5, 2024. doi: 10.4292/wjgpt.v15.i6.97381
Drug | Mechanism of action | Side effects | Stage of clinical trials |
Vitamin E | Antioxidant, reduces oxidative stress, modulates NF-kB pathway | Nausea, diarrhea, increased bleeding risk, prostate cancer concerns | Approved for use in NAFLD/NASH, widely recommended |
GLP-1 RAs (e.g., Semaglutide, Liraglutide) | Increases insulin secretion, suppresses glucagon, reduces steatosis and inflammation | Nausea, diarrhea, risk of pancreatitis | Phase II and III trials ongoing |
Pioglitazone | Activates PPAR-γ, improves insulin sensitivity, reduces liver fat | Weight gain, fluid retention, bone loss, risk of heart failure | Phase II and III trials completed |
Obeticholic Acid | FXR agonist, reduces hepatic inflammation and fibrosis, promotes bile secretion | Pruritus, dyslipidemia (increased LDL, decreased HDL), fatigue | Phase III trials (REGENERATE study) |
Lanifibranor | Pan-PPAR agonist, modulates lipid metabolism, reduces inflammation | Fatigue, nausea, diarrhea | Phase III trials ongoing |
Saroglitazar | Dual PPAR-α/γ agonist, reduces liver fat, improves insulin resistance | Gastrointestinal symptoms, rash | Phase II trials ongoing |
Cenicriviroc | CCR2/CCR5 antagonist, reduces liver inflammation and fibrosis | Fatigue, diarrhea, headaches | Phase III trials (AURORA study) |
Selonsertib | ASK1 inhibitor, reduces fibrosis and inflammation | Nausea, diarrhea, fatigue | Failed in Phase III trials |
Diagnostic technique | Method | Advantages | Limitations |
Liver biopsy | Invasive procedure, histological assessment | Gold standard, provides detailed fibrosis staging | Invasive, sampling variability, associated risks |
Vibration-controlled transient elastography | Ultrasound-based, measures liver stiffness | Non-invasive, widely used | Less accurate in obese patients, influenced by inflammation |
MRE | MRI-based imaging, measures tissue stiffness | More accurate than Fibroscan for fibrosis and steatosis | High cost, limited availability |
APRI | Blood-based, calculates fibrosis risk | Non-invasive, low cost | Lower sensitivity in early fibrosis |
ELF test | Blood-based, measures biomarkers of fibrosis | High sensitivity and specificity for advanced fibrosis | Costly, limited access in some regions |
- Citation: Abdel-Samiee M, Ibrahim ES, Kohla M, Abdelsameea E, Salama M. Regression of hepatic fibrosis after pharmacological therapy for nonalcoholic steatohepatitis. World J Gastrointest Pharmacol Ther 2024; 15(6): 97381
- URL: https://www.wjgnet.com/2150-5349/full/v15/i6/97381.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v15.i6.97381